Werewolf Therapeutics, Inc. Material Event - 8-K Summary

---

Werewolf Therapeutics, Inc. faces a critical juncture, announcing a drastic restructuring to survive a severe cash shortage. This summary details the company's recent 8-K filing, outlining significant workforce reductions, executive departures, and a fundamental shift in strategy.

1. Event Description (What Happened)

On February 9, 2026, Werewolf Therapeutics, Inc.'s Board of Directors approved a sweeping corporate restructuring plan. This plan slashes the company's total workforce by a dramatic 64%, impacting nearly two-thirds of its employees. Concurrently, key executives Timothy W. Trost, Chief Financial Officer (CFO), and Dr. Randi Isaacs, Chief Medical Officer (CMO), are departing their roles. Michael Urban, previously Vice President of Finance, assumes the role of principal financial and accounting officer.

Werewolf Therapeutics undertook these actions to significantly reduce operating expenses and extend its cash runway. This decision follows a period since late last year where the company failed to secure additional capital, leading to a critical cash shortage. The restructuring marks a fundamental shift in strategy, moving from broad pipeline development to a highly focused, survival-oriented approach. The company will now prioritize its most advanced and promising proprietary INDUKINE™ programs, WTX-124 and WTX-330, both currently in preclinical development. Werewolf Therapeutics actively evaluates strategic alternatives to maximize value for these programs, including seeking partnerships, collaborations, or out-licensing opportunities, as it can no longer independently advance them. Other programs are likely paused or discontinued.

2. Event Date/Timeline

The Board of Directors approved the restructuring plan on February 9, 2026. The company expects to complete the workforce reduction and executive transitions by February 13, 2026.

3. Impact Assessment (Who/What Is Affected)

• Employees: Werewolf Therapeutics will lay off 64% of its workforce, creating immediate hardship for those affected. Remaining employees will likely face increased workloads and uncertainty. The departing CFO and CMO will receive severance packages and assist with transitions.
• Investors: Anticipate significant stock price volatility and downward pressure due to severe financial distress and a fundamental shift in strategy. Werewolf Therapeutics' investment profile now shifts to extremely high risk.
• The Company: Werewolf Therapeutics will operate as a significantly smaller entity with reduced capacity. This necessitates a complete re-evaluation of its strategic direction and operational model. The company will substantially curtail its research and development (R&D) activities, pausing, de-prioritizing, or discontinuing many programs.
• Patients: While the filing does not directly state the impact on patients, a smaller team and fewer resources suggest a slower pace of drug development, potentially delaying or halting promising new treatments.

4. Financial Impact (If Applicable)

The company anticipates incurring a one-time cash charge of approximately $4.1 million for severance payments and benefits to laid-off employees.

The primary goal of these drastic cuts is to extend the company's cash runway. While the filing does not state a precise figure, these actions aim to extend cash resources. Based on similar situations, these measures likely intend to extend their cash resources from an estimated few months to potentially late 2027 or early 2028. This estimate assumes no further significant capital raises or partnerships, as the original filing did not provide a precise figure. The company's inability to secure sufficient new funding since late last year led to a critical cash shortage, necessitating these expense reductions.

5. Key Takeaways for Investors

• Extreme Volatility & High Risk: This event dramatically increases Werewolf Therapeutics' risk profile. The stock will likely be highly volatile, and the company's long-term viability now heavily depends on securing partnerships or further funding.
• Cash Burn is Key: The primary goal of these cuts is to extend the cash runway. Investors must closely monitor future financial reports for updates on the company's cash position and burn rate. Werewolf Therapeutics' ability to survive hinges on this.
• Partnerships are Crucial: The future of the prioritized WTX-124 and WTX-330 programs, and potentially the company itself, depends on successful strategic partnerships, collaborations, or out-licensing opportunities. Any announcements regarding these will prove critical.
• Dilution Risk: If the company needs to raise more capital in the future, it will likely come at a significant cost to existing shareholders through further stock dilution.
• Biotech Reality: This serves as a stark reminder of the inherent risks in biotech investing, where even promising science can be derailed by financial constraints and the inability to secure funding.